Legislative changes to hamper innovative drugs market in Central Europe between 2012 and 2014
Innovative markets to decline in some CE countries
In terms of the rate of change on the innovative market, huge differences are to be observed in the development of this subgroup in individual countries. In Bulgaria the growth rate will be substantial – around 14% per annum on average, whereas in the Czech Republic and Romania it will fluctuate around 7% and 4% respectively. In Poland the innovative drug market is expected to develop at a 0% rate and, in 2014, it should, therefore, return to its 2011 value. In Slovakia and Hungary the year-on-year changes will be negative. On the other hand, in all of the CE countries analysed, between 2012 and 2014 the average annual rates of change in the value of the generic drugs market will be positive.
Szell Kalman Plan implications for Hungary
In general, in Hungary the climate for innovative medicines is the most unfavourable in CE. “2009 and 2010 have already been difficult for innovative drug manufacturers in the country. Many manufacturers complained that the country had not supported innovations. In 2011 the situation became even worse, with the introduction of changes to R&D expense deductions” says Agnieszka Skonieczna, PMR Senior Pharmaceutical Market Analyst and the report co-author. In addition, in recent months most medicines which appeared on the reimbursement lists in the country were generic. For example, the October 2011 update to the reimbursement list included 21 generic and eight innovative drugs.
In 2011 a structural reform programme based on the Szell Kalman Plan was launched in Hungary. The programme is aimed at consolidating the Hungarian public sector by instigating structural reforms, boosting economic growth, encouraging an increase in employment levels and enhancing the competitiveness of Hungary’s economy, and it will have several consequences for the pharmaceutical industry in the country.
The main aim of the plan in to reduce the reimbursement costs for the OEP (National Health Insurance Fund) and drug prices for patients which will have the most severe effect on innovative medicines. In 2012 the drug budget is expected to be HUF 83bn (€301m) less than that of 2010, and in 2013 and 2014 budget cuts will fluctuate around HUF 120bn (€430m) each year. In February 2012 the Hungarian government announced that it was looking for further savings, and the situation could, therefore, become even worse in the future.
Slovakia favours generic medicines
Government reimbursement policy in Slovakia is favouring generics, rather than innovative drugs. This is why a slight reduction in the latter is expected in the foreseeable future, whereas the overall market will grow. There are several reasons for this. First of all, in Slovakia the market share of original drugs by value is relatively high in comparison with those of other countries, and this market subdivision, which is quite saturated, will develop at a slower rate than that of generics. Furthermore, the country’s policy in the pharmaceutical arena does not support innovative companies. In the five reference pricing rounds which have taken place so far, the prices of several hundred medicines have been reduced, and most of these were innovative medicines. The legal changes are also designed to support the generic market rather than that of innovative medicine. For example, in Slovakia a new reference pricing system (in which a drug price will be set at the level of the lowest price in a basket of prices of all of the EU countries) has come into force, with the aim of reducing medicine prices further. In addition, the prescription of APIs, instead of brand names, has been introduced in the country, and this could boost sales of generic medicines. Obligatory generic substitution at pharmacies is also planned to be standard practice in the country.
This press release is based on information contained in the latest PMR report entitled “Generic and innovative drugs market in Central Europe 2012. Comparative analysis, reimbursement policies and development forecasts for 2012-2014” http://www.pmrpublications.com/product/Generic-and-innovative-drugs-market-Central-Europe-2012.
For more information on the report please contact:
tel. /48/ 12 618 90 00
This release was published on openPR.
Permanent link to this press release:
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Legislative changes to hamper innovative drugs market in Central Europe between 2012 and 2014 here
News-ID: 218166 • Views: 2813
More Releases from PMR Ltd
60% of Polish SMEs use IT services
Approx. 60% of small and medium sized enterprises use IT services in Poland. Some 30% of SMEs declare to employ people responsible for IT. The number of portable computers used by SMEs has been growing. On average, there are five such computers per one SME. The proportion of companies which use EU funds to finance ICT development has gone down over the last two years. Use of IT services According to the
Ukrainian IT industry to keep on growing in 2012-2013
In the last two years Ukrainian IT market has been recovering after a sharp decline experienced in 2009. The market will continue to record double digit growth rates in 2012-2013. The macroeconomic and political situation will remain of crucial importance in the country. Current situation and key trends According to the latest report “IT market in Ukraine 2012. Development forecasts for 2012-2017” published by PMR, a market research company, the total
Retail grocery market to provide €117bn in 2014 in the CE region
PMR estimates that in 2011 the grocery market in six Central European (CE) countries was worth nearly €107bn, 2.8% more than the previous year when expressed in local currencies. The increase was generated foremost by the discount stores and supermarket segments, and was driven by the skyrocketing prices of foodstuffs. Schwarz Group, which operates the Lidl and Kaufland chains, is a leading grocery player in the CE region – as
Hungarian construction market to recover in 2013-2014
After a poor 2009-2012 for the Hungarian construction industry, from 2013 a visible market recovery is expected. The growth in 2013-2014 will result from the intense execution of EU co-financed infrastructure investments as well as some revival in building construction, particularly in non-residential buildings. According to the research company PMR’s latest report, entitled “Construction sector in Hungary 2012 – Development forecasts for 2012-2014”, weak macroeconomic environment, falling investment demand and poor
More Releases for Slovakia
Payments Landscape Market in Slovakia: Opportunities and Risks to 2021
Orbisresearch.com added latest 49 pages report “Payments Landscape in Slovakia: Opportunities and Risks to 2021” in its store. GlobalData’s "Payments Landscape in Slovakia: Opportunities and Risks to 2021", report provides detailed analysis of market trends in the Slovakian cards and payments industry. It provides values and volumes for a number of key performance indicators in the industry, including cash, payment cards, credit transfers, direct debit, and cheques during the review-period (2013-17e). Request
Service Station Retailing in Slovakia Market Research Report
MarketResearchReports.Biz announces addition of new report "Service Station Retailing in Slovakia Market" to its database. Service Station Retail Slovakia Report , a Sector Report by GlobalData, provides an executive-level overview of the Slovakian service station market today, with forecasts of values and volumes up to 2021. It delivers deep quantitative and qualitative insight into the fuel market, analyzing key trends in the market based on in depth interviews with major fuel
Agrochemicals Market in Slovakia
ReportsWorldwide has announced the addition of a new report title Slovakia: Agrochemicals: Market Intelligence (2016-2021) to its growing collection of premium market research reports. The report “Slovakia: Agrochemicals: Market Intelligence (2016-2021)” provides market intelligence on the different market segments, based on type, active ingredient, formulation, crop, and pest. Market size and forecast (2016-2021) has been provided in terms of both, value (000 USD) and volume (000 KG) in the report. A
New photovoltaic power plants at Horovce and Mokrá Lúka, Slovakia
The development of four photovoltaic power plants has commenced at the start of April 2011, this time in the areas Mokrá Lúka and Horovce, Slovakia. New solar power plants will take up an area of 8.6 ha and a total of 18 090 highly effective PhonoSolar PS190M-24F panels we used in their development. These panels are manufactured from durable materials and undergo a very strict inspection. Complete development of all complexes
EFEKTIM started the construction of photovoltaic power plants in Slovakia
At the start of April 2011 EFEKTIM started another development of new solar power plants, the FVE Kresandra and FVE Power Plant 1 nearby Mokra Luka in Slovakia. Technologically prepared lot is already fenced in and individual racks are installed. AC cabling and grounding are also in place. Switchboards and frames are being currently assembled. The construction of these solar power plants will require a total of 10 314 high efficient
Construction in Slovakia set to resume growth
Over the past two years, Slovak construction has been lacerated by the economic crisis. The reduction in purchasing power, the low level of business confidence, high unemployment and a scarcity of capital discouraged construction projects in the country in 2009 and 2010. Another negative factors which affected the Slovak construction industry in 2009-2010 were: o insufficient demand for construction, particularly in the subgroup of building construction o limited funding for construction, reduced access to